Pharmacytimes http://www.pharmacytimes.com/rss PharmacyTimes.com offers continuing education (CE) courses, career guidance for pharmacy students, online-only articles, digital versions of the print issue, and more, that are essential to pharmacists en-us Tue, 23 Jan 18 07:43:24 +0000 Tue, 23 Jan 18 07:43:24 +0000 Pharmacists Rank Among 100 Best, Highest Paying Jobs of 2018 http://www.pharmacytimes.com/news/pharmacists-rank-among-100-best-highest-paying-jobs-of-2018 http://www.pharmacytimes.com/news/pharmacists-rank-among-100-best-highest-paying-jobs-of-2018 US News &amp; World Report recently released its ranking of the highest paying and best overall jobs of 2018, and pharmacists made the cut for both lists.<br /> &nbsp; Thu, 18 Jan 18 19:03:00 +0000 FDA Aims to Improve Access to Clinical Trial Info for New Drugs http://www.pharmacytimes.com/product-news/fda-aims-to-improve-access-to-clinical-trial-info-for-new-drugs http://www.pharmacytimes.com/product-news/fda-aims-to-improve-access-to-clinical-trial-info-for-new-drugs To better enhance transparency around FDA drug approval decisions, the agency is launching a pilot program aimed at improving provider access to key information related to new drugs.<br /> &nbsp; Wed, 17 Jan 18 13:51:00 +0000 NCPA and Other Health Care Groups Join Together to Support DIR Fee Reforms http://www.pharmacytimes.com/news/ncpa-and-other-health-care-groups-join-together-to-support-dir-fee-reforms http://www.pharmacytimes.com/news/ncpa-and-other-health-care-groups-join-together-to-support-dir-fee-reforms More than 115 health care organizations have teamed up to urge the Centers for Medicare and Medicaid Services (CMS) to take action on retroactive direct and indirect renumeration (DIR) fees.&nbsp; Mon, 15 Jan 18 15:04:00 +0000 The Power of One: How Partnering Can Enhance Your Independent Brand http://www.pharmacytimes.com/news/the-power-of-one-how-partnering-can-enhance-your-independent-brand http://www.pharmacytimes.com/news/the-power-of-one-how-partnering-can-enhance-your-independent-brand Sat, 13 Jan 18 17:39:00 +0000 FDA Updates Labeling for Opioid-Containing Medications to Limit Use in Children http://www.pharmacytimes.com/product-news/fda-updates-labeling-for-opioidcontaining-medications-to-limit-use-in-children http://www.pharmacytimes.com/product-news/fda-updates-labeling-for-opioidcontaining-medications-to-limit-use-in-children Officials with the FDA have announced labeling changes to prescription opioid cough and cold medications that contain codeine or hydrocodone. Thu, 11 Jan 18 19:54:00 +0000 Potential Alternative to Carbapenems for Hospital-Acquired Pneumonia? http://www.pharmacytimes.com/product-news/potential-alternative-to-carbapenems-for-hospitalacquired-pneumonia http://www.pharmacytimes.com/product-news/potential-alternative-to-carbapenems-for-hospitalacquired-pneumonia Ceftazidime-avibactam, a new antibiotic combination, may be an effective alternative to carbapenem meropenem for the treatment of hospital-acquired pneumonia associated with antimicrobial-resistant Gram-negative pathogens. Wed, 10 Jan 18 14:13:00 +0000 Eravacycline: Potential Clinical Significance for Treating Infections http://www.pharmacytimes.com/product-news/eravacycline-potential-clinical-significance-for-treating-infections http://www.pharmacytimes.com/product-news/eravacycline-potential-clinical-significance-for-treating-infections Eravacycline is an investigational drug candidate for the treatment of complicated intra-abdominal infections.&nbsp; Tue, 09 Jan 18 08:00:00 +0000 Treatment Options for IA, Mucormycosis Expanding http://www.pharmacytimes.com/news/treatment-options-for-ia-mucormycosis-expanding- http://www.pharmacytimes.com/news/treatment-options-for-ia-mucormycosis-expanding- The development of mold-active azoles has led to enormous advancements in both prevention and treatment of invasive fungal infections.&nbsp; Fri, 05 Jan 18 08:33:00 +0000 Opinion Piece Takes Aim at PBMs http://www.pharmacytimes.com/news/opinion-piece-takes-aim-at-pbms http://www.pharmacytimes.com/news/opinion-piece-takes-aim-at-pbms Fri, 05 Jan 18 07:00:00 +0000 US Cancer Mortality Declines, But More Work to be Done http://www.pharmacytimes.com/news/us-cancer-mortality-declines-but-more-work-to-be-done http://www.pharmacytimes.com/news/us-cancer-mortality-declines-but-more-work-to-be-done Deaths related directly to cancer continue to decline in the United States, resulting in nearly 2.4 million fewer cancer-related deaths. Thu, 04 Jan 18 19:47:00 +0000 FDA Grants Breakthrough Therapy Designation to Rare Blood Disorder Treatment http://www.pharmacytimes.com/product-news/fda-grants-breakthrough-therapy-designation-to-rare-blood-disorder-treatment http://www.pharmacytimes.com/product-news/fda-grants-breakthrough-therapy-designation-to-rare-blood-disorder-treatment Officials with the FDA have granted breakthrough therapy designation to eltrombopag (Promacta, Novartis) for first-line use, in combination with standard immunosuppressive therapy, in patients with severe aplastic anemia. Thu, 04 Jan 18 09:00:00 +0000 FDA Goals for 2018: Speed Up Generic Drug Approvals, Enhance Competition http://www.pharmacytimes.com/product-news/fda-goals-for-2018-speed-up-generic-drug-approvals-enhance-competition http://www.pharmacytimes.com/product-news/fda-goals-for-2018-speed-up-generic-drug-approvals-enhance-competition As part of their Drug Competition Action Plan, officials with the FDA have announced additional steps to encourage competition in the generic drug market. Wed, 03 Jan 18 18:45:00 +0000 Tetraphase Submits NDA for Investigational Drug for Complicated Intra-Abdominal Infections http://www.pharmacytimes.com/product-news/tetraphase-submits-nda-for-investigational-drug-for-complicated-intraabdominal-infections http://www.pharmacytimes.com/product-news/tetraphase-submits-nda-for-investigational-drug-for-complicated-intraabdominal-infections Tetraphase Pharmaceuticals today announced submission of its new drug application (NDA) to the FDA for eravacycline, in IV form, for the treatment of complicated intra-abdominal infections (cIAI).&nbsp; Wed, 03 Jan 18 18:38:00 +0000 What's on the Horizon for Drugs in 2018? http://www.pharmacytimes.com/product-news/whats-on-the-horizon-for-drugs-in-2018 http://www.pharmacytimes.com/product-news/whats-on-the-horizon-for-drugs-in-2018 With 2017 behind us, we&rsquo;re looking ahead at the next year for what&rsquo;s on the horizon in pharmacy. Fri, 29 Dec 17 15:17:00 +0000 FDA OKs Marketing of Shock Wave Device for Diabetic Foot Ulcers http://www.pharmacytimes.com/product-news/fda-oks-marketing-of-shock-wave-device-for-diabetic-foot-ulcers http://www.pharmacytimes.com/product-news/fda-oks-marketing-of-shock-wave-device-for-diabetic-foot-ulcers The FDA has permitted marketing of a new device intended to treat diabetic foot ulcers. Thu, 28 Dec 17 21:00:00 +0000 Top 10 Most Read Articles on Pharmacy Times from 2017 http://www.pharmacytimes.com/news/top-10-most-read-articles-on-pharmacy-times-from-2017 http://www.pharmacytimes.com/news/top-10-most-read-articles-on-pharmacy-times-from-2017 A look at some of the top read articles on <em>Pharmacy Times</em> from 2017.&nbsp; Thu, 28 Dec 17 16:26:00 +0000 10 FDA Approvals to Know from 2017 http://www.pharmacytimes.com/product-news/10-fda-approvals-to-know-from-2017 http://www.pharmacytimes.com/product-news/10-fda-approvals-to-know-from-2017 With the New Year on our heels, let&rsquo;s look back on some of the most noteworthy FDA approvals of 2017.<br /> &nbsp; Wed, 27 Dec 17 15:12:00 +0000 FDA Approves Sickle Cell Anemia Drug http://www.pharmacytimes.com/product-news/fda-approves-sickle-cell-anemia-drug http://www.pharmacytimes.com/product-news/fda-approves-sickle-cell-anemia-drug Hydroxyurea is indicated to decrease the prevalence of painful crises and the need for transfusions in pediatric patients aged 2 years and older with sickle cell anemia with moderate-to-severe painful crises. Fri, 22 Dec 17 10:00:00 +0000 Nivolumab Receives FDA Approval as an Adjuvant Melanoma Treatment http://www.pharmacytimes.com/product-news/nivolumab-receives-fda-approval-as-an-adjuvant-melanoma-treatment http://www.pharmacytimes.com/product-news/nivolumab-receives-fda-approval-as-an-adjuvant-melanoma-treatment The FDA recently approved nivolumab (Opdivo) for the treatment of patients with melanoma whose disease has spread to the lymph nodes or those with metastatic disease who have undergone resection, according to a press release.&nbsp; Fri, 22 Dec 17 09:30:00 +0000 FDA Approves Advanced Renal Cell Carcinoma Treatment http://www.pharmacytimes.com/product-news/fda-approves-advanced-renal-cell-carcinoma-treatment http://www.pharmacytimes.com/product-news/fda-approves-advanced-renal-cell-carcinoma-treatment Officials with the FDA recently approved&nbsp;cabozantinib (Cabometyx) for the first-line treatment of patients with advanced renal cell carcinoma (RCC), according to a press release.&nbsp; Fri, 22 Dec 17 09:00:00 +0000 FDA Grants Accelerated Approval to Chronic Myelogenous Leukemia Drug http://www.pharmacytimes.com/product-news/fda-grants-accelerated-approval-to-chronic-myelogenous-leukemia-drug http://www.pharmacytimes.com/product-news/fda-grants-accelerated-approval-to-chronic-myelogenous-leukemia-drug Officials with the FDA granted accelerated approval to&nbsp;bosutinib (Bosulif)&nbsp;for the treatment of patients with&nbsp;newly-diagnosed chronic phase (CP) Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML). Fri, 22 Dec 17 08:30:00 +0000 FDA OKs Drug for Critically Low Blood Pressure in Septic Shock http://www.pharmacytimes.com/product-news/fda-oks-drug-for-critically-low-blood-pressure-in-septic-shock http://www.pharmacytimes.com/product-news/fda-oks-drug-for-critically-low-blood-pressure-in-septic-shock Officials with the FDA have approved angiotensin II (Giapreza, La Jolla Pharmaceutical Company) injection for intravenous infusion to treat dangerously low blood pressure in adults with septic or other distributive shock. Fri, 22 Dec 17 01:00:00 +0000 FDA Approves HER2+ Breast Cancer Therapy http://www.pharmacytimes.com/product-news/fda-approves-her2-breast-cancer-therapy http://www.pharmacytimes.com/product-news/fda-approves-her2-breast-cancer-therapy Officials with the FDA have approved pertuzumab (Perjeta, Roche) in combination with&nbsp;trastuzumab and chemotherapy&nbsp;as an adjuvant therapy for patients with early-stage human epidermal growth factor receptor 2 positive (HER2+) breast cancer who are at high risk of experiencing recurrence.&nbsp; Thu, 21 Dec 17 16:53:00 +0000 FDA OKs SGLT2 Inhibitor Ertugliflozin for Type 2 Diabetes http://www.pharmacytimes.com/product-news/fda-oks-sglt2-inhibitor-ertugliflozin-for-type-2-diabetes http://www.pharmacytimes.com/product-news/fda-oks-sglt2-inhibitor-ertugliflozin-for-type-2-diabetes Officials with the FDA have approved ertugliflozin (Steglatro, Merck and Pfizer) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Thu, 21 Dec 17 01:00:00 +0000 FDA Rules on OTC Antiseptic Soaps http://www.pharmacytimes.com/product-news/fda-rules-on-otc-antiseptic-soaps http://www.pharmacytimes.com/product-news/fda-rules-on-otc-antiseptic-soaps Officials with the FDA have finalized a rule that bans 24 active ingredients, including triclosan, from being marketed and sold in OTC health care antiseptic products. Wed, 20 Dec 17 10:00:00 +0000